Fremont, CA, United States
Fremont, CA, United States

Time filter

Source Type

Kyle J.L.,U.S. Department of Agriculture | Kyle J.L.,Eureka Genomics | Cummings C.A.,Life Technologies | Parker C.T.,U.S. Department of Agriculture | And 17 more authors.
Journal of Bacteriology | Year: 2012

Enteropathogenic Escherichia coli (EPEC) continues to be a leading cause of mortality and morbidity in children around the world. Two EPEC genomes have been fully sequenced: those of EPEC O127:H6 strain E2348/69 (United Kingdom, 1969) and EPEC O55:H7 strain CB9615 (Germany, 2003). The O55:H7 serotype is a recent precursor to the virulent enterohemorrhagic E. coli O157:H7. To explore the diversity of O55:H7 and better understand the clonal evolution of O157:H7, we fully sequenced EPEC O55:H7 strain RM12579 (California, 1974), which was collected 1 year before the first U.S. isolate of O157:H7 was identified in California. Phage-related sequences accounted for nearly all differences between the two O55:H7 strains. Additionally, O55:H7 and O157:H7 strains were tested for the presence and insertion sites of Shiga toxin gene (stx)-containing bacteriophages. Analysis of non-phage-associated genes supported core elements of previous O157:H7 stepwise evolutionary models, whereas phage composition and insertion analyses suggested a key refinement. Specifically, the placement and presence of lambda-like bacteriophages (including those containing stx) should not be considered stable evolutionary markers or be required in placing O55:H7 and O157:H7 strains within the stepwise evolutionary models. Additionally, we suggest that a 10.9-kb region (block 172) previously believed unique to O55:H7 strains can be used to identify early O157:H7 strains. Finally, we defined two subsets of O55:H7 strains that share an as-yet-unobserved or extinct common ancestor with O157:H7 strains. Exploration of O55:H7 diversity improved our understanding of the evolution of E. coli O157:H7 and suggested a key revision to accommodate existing and future configurations of stx-containing bacteriophages into current models. © 2012, American Society for Microbiology.


Rivers A.R.,Joint Genome Institute | Burns A.S.,University of Georgia | Burns A.S.,Georgia Institute of Technology | Chan L.-K.,WaferGen Biosystems | Moran M.A.,University of Georgia
Frontiers in Microbiology | Year: 2016

In oligotrophic ocean waters where bacteria are often subjected to chronic nutrient limitation, community transcriptome sequencing has pointed to the presence of highly abundant small RNAs (sRNAs). The role of sRNAs in regulating response to nutrient stress was investigated in a model heterotrophic marine bacterium Ruegeria pomeroyi grown in continuous culture under carbon (C) and nitrogen (N) limitation. RNAseq analysis identified 99 putative sRNAs. Sixty-nine were cis-encoded and located antisense to a presumed target gene. Thirty were trans-encoded and initial target prediction was performed computationally. The most prevalent functional roles of genes anti-sense to the cis-sRNAs were transport, cell-cell interactions, signal transduction, and transcriptional regulation. Most sRNAs were transcribed equally under both C and N limitation, and may be involved in a general stress response. However, 14 were regulated differentially between the C and N treatments and may respond to specific nutrient limitations. A network analysis of the predicted target genes of the R. pomeroyi cis-sRNAs indicated that they average fewer connections than typical protein-encoding genes, and appear to be more important in peripheral or niche-defining functions encoded in the pan genome. © 2016 Rivers, Burns, Chan and Moran.


MOUNTAIN VIEW, Calif., Dec. 20, 2016 /PRNewswire/ -- Admera Health has been awarded the 2016 North American Frost & Sullivan Award for Technology Innovation for delivering a range of  tests to the next-generation sequencing (NGS) molecular diagnostics market. These tests include PGxOne™ Plus for pharmacogenomics, a Cardiovascular Test Portfolio and a growing Oncology Test Portfolio. These products have proved highly valuable across the entire continuum of patient care, starting from screening, diagnosis, treatment to monitoring and patient management. Click here to view the complete Frost Multimedia Wire: http://best-practices.frost-multimedia-wire.com/admera-health/ "Admera's flagship PGxOne™ Plus pharmacogenomics test conducts a comprehensive analysis of nearly 200 variants in 50 genes to gauge the way a patient will respond to specific drugs," said Frost & Sullivan Senior Research Analyst Madhumitha Rangesa. "Based on the patient's genetic makeup, the PGxOne™ Plus recommends more than 220 commercial drugs for pain management, cardiovascular disease, psychiatry, cancer and other indications." PGxOne™ Plus report recommendations include considering alternatives when specific drugs should be avoided, dosage adjustment information when available, use with caution, and normal response expected. The clinically relevant results can help guide treatment decisions, which can potentially improve patient care and reduce adverse drug events. Similarly, Admera's genetic testing for inherited cardiovascular diseases, CardioGxOne™, provides clear interpretations for disease diagnosis and the risk assessment of sudden cardiac death. The company also offers cancer testing such as the OncoGxOne™ and OncoGxSelect™. The former is a comprehensive cancer panel that detects a range of genomic variations related to targeted therapies and chemotherapeutic response across multiple cancer types, while the latter aligns with well-established and medically actionable guidelines. Admera has also developed non-invasive cancer mutation detection that analyzes circulated tumor DNA (ctDNA). This liquid biopsy technology can be utilized to guide cancer treatment selection and subsequent patient monitoring. Apart from these products, Admera is creating multiple solutions with high commercialization potential. For instance, AtheroGxOne™, a gene panel specifically for the risk assessment and diagnosis of premature coronary or atherosclerotic disease was launched in April 2016 at the American College of Cardiology. Acknowledging the importance of collaborations to gain a competitive edge, Admera has partnered with WaferGen Biosystems to increase the coverage of the PGxOne™ Plus test. It also has partnerships with the cardiovascular genetics company Health in Code, Rosetta Genomics in the oncology space and has collaborated with hc1® Healthcare Relationship Cloud® to leverage its CRM solutions. "Admera's multiple partnerships support its product marketing and distribution initiatives, as well as help it avail the services of healthcare client management experts," noted Rangesa. "Its fully automated bioinformatics technology platform has uniquely positioned it to compete in the promising digital health management space." Admera's expansive product range and rapidly growing pipeline will reduce the overall cost burden of healthcare, making it richly deserving of the 2016 North American Frost & Sullivan Award for Technology Innovation. Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing and leveraging new technologies, which significantly impacts both the functionality and the customer value of the new products and applications. The award lauds the high R&D spend towards innovation, its relevance to the industry, and the positive impact on brand perception. Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for outstanding achievement in areas such as leadership, technological innovation, customer service, and product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research. Admera Health is a CLIA-certified and CAP-accredited advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, digital health, and providing research use only services. Research and development efforts are dedicated to developing cutting-edge diagnostics that span the continuum of care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is our mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. We are committed to improving the health and well-being of our global community through the direct delivery of personalized, medically actionable results. Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.


Admera Health is transforming precision medicine by covering a diverse range of indications with its flagship PGxOne™ Plus pharmacogenomics test MOUNTAIN VIEW, California, Dec. 20, 2016 /PRNewswire/ -- Admera Health has been awarded the 2016 North American Frost & Sullivan Award for Technology Innovation for delivering a range of  tests to the next-generation sequencing (NGS) molecular diagnostics market. These tests include PGxOne™ Plus for pharmacogenomics, a Cardiovascular Test Portfolio and a growing Oncology Test Portfolio. These products have proved highly valuable across the entire continuum of patient care, starting from screening, diagnosis, treatment to monitoring and patient management. Click here to view the complete Frost Multimedia Wire: http://best-practices.frost-multimedia-wire.com/admera-health/ "Admera's flagship PGxOne™ Plus pharmacogenomics test conducts a comprehensive analysis of nearly 200 variants in 50 genes to gauge the way a patient will respond to specific drugs," said Frost & Sullivan Senior Research Analyst Madhumitha Rangesa. "Based on the patient's genetic makeup, the PGxOne™ Plus recommends more than 220 commercial drugs for pain management, cardiovascular disease, psychiatry, cancer and other indications." PGxOne™ Plus report recommendations include considering alternatives when specific drugs should be avoided, dosage adjustment information when available, use with caution, and normal response expected. The clinically relevant results can help guide treatment decisions, which can potentially improve patient care and reduce adverse drug events. Similarly, Admera's genetic testing for inherited cardiovascular diseases, CardioGxOne™, provides clear interpretations for disease diagnosis and the risk assessment of sudden cardiac death. The company also offers cancer testing such as the OncoGxOne™ and OncoGxSelect™. The former is a comprehensive cancer panel that detects a range of genomic variations related to targeted therapies and chemotherapeutic response across multiple cancer types, while the latter aligns with well-established and medically actionable guidelines. Admera has also developed non-invasive cancer mutation detection that analyzes circulated tumor DNA (ctDNA). This liquid biopsy technology can be utilized to guide cancer treatment selection and subsequent patient monitoring. Apart from these products, Admera is creating multiple solutions with high commercialization potential. For instance, AtheroGxOne™, a gene panel specifically for the risk assessment and diagnosis of premature coronary or atherosclerotic disease was launched in April 2016 at the American College of Cardiology. Acknowledging the importance of collaborations to gain a competitive edge, Admera has partnered with WaferGen Biosystems to increase the coverage of the PGxOne™ Plus test. It also has partnerships with the cardiovascular genetics company Health in Code, Rosetta Genomics in the oncology space and has collaborated with hc1® Healthcare Relationship Cloud® to leverage its CRM solutions. "Admera's multiple partnerships support its product marketing and distribution initiatives, as well as help it avail the services of healthcare client management experts," noted Rangesa. "Its fully automated bioinformatics technology platform has uniquely positioned it to compete in the promising digital health management space." Admera's expansive product range and rapidly growing pipeline will reduce the overall cost burden of healthcare, making it richly deserving of the 2016 North American Frost & Sullivan Award for Technology Innovation. Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing and leveraging new technologies, which significantly impacts both the functionality and the customer value of the new products and applications. The award lauds the high R&D spend towards innovation, its relevance to the industry, and the positive impact on brand perception. Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for outstanding achievement in areas such as leadership, technological innovation, customer service, and product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research. Admera Health is a CLIA-certified and CAP-accredited advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, digital health, and providing research use only services. Research and development efforts are dedicated to developing cutting-edge diagnostics that span the continuum of care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is our mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. We are committed to improving the health and well-being of our global community through the direct delivery of personalized, medically actionable results. Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.


De Wilde B.,Ghent University | Lefever S.,Ghent University | Dong W.,WaferGen Biosystems | Dunne J.,WaferGen Biosystems | And 3 more authors.
BMC Genomics | Year: 2014

Background: Next generation targeted resequencing is replacing Sanger sequencing at high pace in routine genetic diagnosis. The need for well validated, high quality enrichment platforms to complement the bench-top next generation sequencing devices is high.Results: We used the WaferGen Smartchip platform to perform highly parallelized PCR based target enrichment for a set of known cancer genes in a well characterized set of cancer cell lines from the NCI60 panel. Optimization of PCR assay design and cycling conditions resulted in a high enrichment efficiency. We provide proof of a high mutation rediscovery rate and have included technical replicates to enable SNP calling validation demonstrating the high reproducibility of our enrichment platform.Conclusions: Here we present our custom developed quantitative PCR based target enrichment platform. Using highly parallel nanoliter singleplex PCR reactions makes this a flexible and efficient platform. The high mutation validation rate shows this platform's promise as a targeted resequencing method for multi-gene routine sequencing diagnostics. © 2014 De Wilde et al.; licensee BioMed Central Ltd.


Trademark
WaferGen Biosystems | Date: 2011-01-18

Laboratory equipment, namely, micro-incubators and micro-incubator systems comprised of micro-incubators, an electronic instrument for controlling the micro-incubator, tubing, glass bottles, and/or computer software, all for use in growing and differentiating cells all for use in research; laboratory instruments for use in performing polymerase chain reaction (PCR) for scientific and research use; laboratory equipment for scientific and research use, namely, thermal cyclers; laboratory instruments, namely, real-time thermal cyclers used in gene expression, genotyping and life sciences all for use in research; laboratory equipment, namely, micro-incubators and micro-incubator systems comprised of micro-incubators, an electronic instrument for controlling the micro-incubator, tubing, glass bottles, and/or computer software, all for use in growing and differentiating cells all for use in clinical, medical or diagnostic applications.


Trademark
WaferGen Biosystems | Date: 2015-09-28

COMPUTER SOFTWARE FOR SCIENTIFIC AND RESEARCH USE.


Trademark
WaferGen Biosystems | Date: 2015-09-28

Laboratory equipment for scientific and research use, namely, systems comprised of fluid dispenser, imaging station, thermal cycler, computer hardware, control software, analysis software, chips and reagents.


WaferGen Biosystems | Entity website

Reaching Us WaferGen Bio-systems, Inc. offers innovative genomic technology solutions for single-cell analysis and clinical research ...


Loading WaferGen Biosystems collaborators
Loading WaferGen Biosystems collaborators